Search research articles
Contact Us
Filters
Showing results (251-260 of 287) with videos related to
Page
of 29
Sort By:
The Journal of Allergy and Clinical Immunology
|
October 20, 2025
Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies
Ana Maria Giménez-Arnau, Robert Szalewski, Michihiro Hide, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
June 4, 2026
Safety of remibrutinib in chronic spontaneous urticaria: a pooled analysis of REMIX-1 and REMIX-2 trials
Ana Maria Giménez-Arnau, Artem Zharkov, Bin Yang, et al.
Clinical and Translational Allergy
|
March 4, 2026
An International Delphi Study on Barriers to On-Demand Treatment of Hereditary Angioedema Attacks
Aleena Banerji, Emel Aygören-Pürsün, Noemi-Anna Bara, et al.
Journal of the American Academy of Dermatology
|
March 19, 2009
A randomized double-blind trial of intravenous immunoglobulin for pemphigus
Masayuki Amagai, Shigaku Ikeda, Hiroshi Shimizu, et al.
The Journal of Allergy and Clinical Immunology
|
May 28, 2021
Consensus on treatment goals in hereditary angioedema: A global Delphi initiative
Marcus Maurer, Emel Aygören-Pürsün, Aleena Banerji, et al.
The World Allergy Organization Journal
|
June 23, 2025
Diagnostic testing for chronic spontaneous urticaria with or without angioedema: The do's, don't and maybe's
Jonathan A Bernstein, Ignacio Ansotegui, Riccardo Asero, et al.
Research Involvement and Engagement
|
November 30, 2023
Enhancing evidence-informed policymaking in medicine and healthcare: stakeholder involvement in the Commons Project for rare diseases in Japan
Atsushi Kogetsu, Moeko Isono, Tatsuki Aikyo, et al.
Journal of the American Academy of Dermatology
|
August 3, 2019
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study
Mette Deleuran, Diamant Thaçi, Lisa A Beck, et al.
JAMA Dermatology
|
July 17, 2024
Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation
Reineke Soegiharto, Mehran Alizadeh Aghdam, Jennifer Astrup Sørensen, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
March 14, 2026
Performance of omalizumab in patients with mast cell-mediated angioedema with and without wheals
Sara van der Kamp, Reineke Soegiharto, Jennifer Astrup Sørensen, et al.
Page
of 29
Search research articles
Search
Showing results (251-260 of 287) with videos related to
Sort By:
Page
of 29
The Journal of Allergy and Clinical Immunology
|
October 20, 2025
Remibrutinib in chronic spontaneous urticaria: 52-week results from two phase 3 studies
Ana Maria Giménez-Arnau, Robert Szalewski, Michihiro Hide, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
June 4, 2026
Safety of remibrutinib in chronic spontaneous urticaria: a pooled analysis of REMIX-1 and REMIX-2 trials
Ana Maria Giménez-Arnau, Artem Zharkov, Bin Yang, et al.
Clinical and Translational Allergy
|
March 4, 2026
An International Delphi Study on Barriers to On-Demand Treatment of Hereditary Angioedema Attacks
Aleena Banerji, Emel Aygören-Pürsün, Noemi-Anna Bara, et al.
Journal of the American Academy of Dermatology
|
March 19, 2009
A randomized double-blind trial of intravenous immunoglobulin for pemphigus
Masayuki Amagai, Shigaku Ikeda, Hiroshi Shimizu, et al.
The Journal of Allergy and Clinical Immunology
|
May 28, 2021
Consensus on treatment goals in hereditary angioedema: A global Delphi initiative
Marcus Maurer, Emel Aygören-Pürsün, Aleena Banerji, et al.
The World Allergy Organization Journal
|
June 23, 2025
Diagnostic testing for chronic spontaneous urticaria with or without angioedema: The do's, don't and maybe's
Jonathan A Bernstein, Ignacio Ansotegui, Riccardo Asero, et al.
Research Involvement and Engagement
|
November 30, 2023
Enhancing evidence-informed policymaking in medicine and healthcare: stakeholder involvement in the Commons Project for rare diseases in Japan
Atsushi Kogetsu, Moeko Isono, Tatsuki Aikyo, et al.
Journal of the American Academy of Dermatology
|
August 3, 2019
Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study
Mette Deleuran, Diamant Thaçi, Lisa A Beck, et al.
JAMA Dermatology
|
July 17, 2024
Multinational Drug Survival Study of Omalizumab in Patients With Chronic Urticaria and Potential Predictors for Discontinuation
Reineke Soegiharto, Mehran Alizadeh Aghdam, Jennifer Astrup Sørensen, et al.
The Journal of Allergy and Clinical Immunology. in Practice
|
March 14, 2026
Performance of omalizumab in patients with mast cell-mediated angioedema with and without wheals
Sara van der Kamp, Reineke Soegiharto, Jennifer Astrup Sørensen, et al.
Page
of 29